利用免疫组织化学和原位杂交技术鉴定人肥大细胞中的分泌型白细胞蛋白酶抑制剂（SLPI）。
Identification of SLPI (secretory leukocyte protease inhibitor) in human mast cells using immunohistochemistry and in situ hybridisation.
作者信息
Westin U, Polling A, Ljungkrantz I, Ohlsson K
机构信息
Department of Otorhinolaryngology, University Hospital of Malmö, University of Lund, Sweden.
出版信息
Biol Chem. 1999 Apr;380(4):489-93. doi: 10.1515/BC.1999.063.
Recently interest has been focused on secretory leucocyte protease inhibitor (SLPI) and its role in immediate hypersensitive reactions, possibly by inhibiting mast cell chymase. The purpose of this investigation was to show whether or not SLPI is produced in mast cells. Double-immunolabelling revealed that SLPI coexists with mast cell tryptase (60%) and chymase (37%). On the other hand, in situ hybridisation studies demonstrated the expression of SLPI mRNA in all mast cells. The differences in results can be attributed to the fact that in situ hybridisation is a more sensitive method than immunohistochemistry. Hence, we conclude that SLPI is produced in human tonsillar mast cells.
最近，人们的兴趣集中在分泌型白细胞蛋白酶抑制剂（SLPI）及其在速发型过敏反应中的作用，可能是通过抑制肥大细胞糜蛋白酶来实现的。本研究的目的是证明肥大细胞中是否产生SLPI。双重免疫标记显示SLPI与肥大细胞类胰蛋白酶（60%）和糜蛋白酶（37%）共存。另一方面，原位杂交研究证明了所有肥大细胞中SLPI mRNA的表达。结果的差异可归因于原位杂交是一种比免疫组织化学更敏感的方法这一事实。因此，我们得出结论，SLPI是在人扁桃体肥大细胞中产生的。
Zotero 插件